EP3939999A1 — Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
Assigned to Fundacion del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III FSP CNIO · Expires 2022-01-19 · 4y expired
What this patent protects
The present invention relates to neutralizing antibodies which specifically recognize the interleukin 11 receptor alpha subunit (IL11RA) extracellular domain and to antibody drug conjugates (ADCs) comprising a therapeutic agent and said neutralizing antibodies. The invention also…
USPTO Abstract
The present invention relates to neutralizing antibodies which specifically recognize the interleukin 11 receptor alpha subunit (IL11RA) extracellular domain and to antibody drug conjugates (ADCs) comprising a therapeutic agent and said neutralizing antibodies. The invention also relates to a method for detecting the IL-11 receptor, to pharmaceutical compositions and to the use of said antibodies or ADCs in the treatment of diseases characterized by an increased IL11RA signaling.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.